The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index; 16 of the 83 sources its claims cite were checked for support.
Abstract
Human models of emotional processing suggest that the direct effect of successful antidepressant drug treatment may be to modify biases in the processing of emotional information. Negative biases in emotional processing are documented in depression, and single or short-term dosing with conventional antidepressant drugs reverses these biases in depressed patients prior to any subjective change in mood. Antidepressant drug treatments also modulate emotional processing in healthy volunteers, which allows the consideration of the psychological effects of these drugs without the confound of changes in mood. As such, human models of emotional processing may prove to be useful for testing the efficacy of novel treatments and for matching treatments to individual patients or subgroups of patients.
Overview
CoChat Summary
TL;DR
This review argues that successful antidepressant drug treatment directly modifies biased emotional processing, with mood improvement following later through relearning and social interaction. It synthesizes human behavioral and neuroimaging evidence in depressed patients and healthy volunteers, and proposes these models for early treatment prediction and drug screening.
Key findings
- The cognitive neuropsychological model holds that antidepressants directly remediate negative emotional processing biases before subjective mood change; for example, a single dose of the SNRI reboxetine reversed negative biases in depressed patients in the absence of changes in subjective mood or anxiety.
- Early emotional processing changes predict later clinical improvement: increased recognition of happy faces after 2 weeks of reboxetine or citalopram correlated with mood improvement 4 weeks later; neural changes after 2 weeks of escitalopram predicted response 4 weeks later; in older adults, happy face recognition was marginally predictive after 8-week open-label citalopram, becoming significant when social support was included.
- Healthy volunteer studies show antidepressant modulation of emotional processing: 7 days of SSRI or SNRI treatment increased positive relative to negative emotional recall; 7 days of citalopram reduced recognition of anger, fear, disgust, and surprise; single-dose reboxetine increased happy face recognition; single-dose citalopram showed complex effects, including increased happy recognition and increased fear processing.
- The model may help screen putative treatments and detect depressogenic effects: aprepitant showed limited, less consistent effects; GSK424887 had negligible effects; rimonabant produced negative emotional memory biases and was withdrawn in 2009 over depressogenic side effects; mirtazapine and agomelatine showed positive effects; ketamine’s rapid effects may involve retroactive interference with existing memories.
Methods
- Narrative review, not a primary experimental study; it synthesizes human behavioral, pharmacological, and neuroimaging studies in depressed patients and healthy volunteers, plus selected rodent back-translation work.
- Evidence includes single-dose, 7-day, 2-week, and 8-week treatment studies using tasks of emotional memory, facial expression recognition, dot probe attention, emotion-potentiated startle, and fMRI/amygdala responses.
- Main analysis is qualitative synthesis of cited findings; no systematic search, meta-analysis, or new data collection is reported.
Limitations
- Stated: further studies are needed to validate the model with treatments having alternative neurochemical mechanisms; study designs and go/no-go parameters require optimization; the amount of early emotional processing change needed to predict later mood improvement remains to be quantified.
- Stated: single-dose citalopram findings are mixed, with both increases and decreases in amygdala reactivity reported; amygdala response reliability to fearful faces was only moderate over 90 days, implying longer scans and large samples may be needed.
- Evident: as a narrative review, it does not systematically assess publication bias, study quality, or heterogeneity, and it reports no primary sample sizes or effect estimates beyond those cited from included studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 43 Not checked · 25 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Antidepressant treatment modifies this, and hyperactive responses in the amygdala are normalised following 7 days'46 or longer44,45 treatment with an SSRI.”
§ The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment > Neural correlates of depression and antidepressant treatment
What the sources say
- Supportedcites [46] Godlewska BR. Norbury R. Selvaraj S. Cowen PJ. Harmer CJ. Shortterm SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol Med. 2012 41 12 2609 2017 22716999 PMC3488813 source
The Abstract reports that heightened amygdala responses to fearful faces in depressed patients were normalised after 7 days of escitalopram treatment. The Discussion likewise reports a significantly lower response after 7 days compared with placebo. This source supports the 7-day part of the citing sentence; the longer-treatment part is assigned to other citations. (LLM, conf=0.94)
- Supportedcites [44] Fu C. Williams S. Cleare A. et al Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry. 2004 61 9 877 889 15351766 source
The Clinical Assessment and Treatment section identifies fluoxetine as an SSRI given for eight weeks. The Effects of Group × Time section reports that the initially elevated response to sad faces in patients, including the left amygdala, fell significantly after treatment. This supports the citation for treatment longer than seven days; this study did not assess a seven-day outcome. Page numbers are unavailable in our copy. (LLM, conf=0.90)
- Supportedcites [45] Victor TA. Furey ML. Fromm SJ. Ohman A. WC D. D. Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry. 2010 67 11 1128 1134 21041614 PMC3253452 source
The Methods (Antidepressant Drug Treatment) report rescanning patients after eight weeks of the SSRI sertraline. The Abstract (Results) says their amygdala response bias reversed toward the normative pattern after treatment. In the citing sentence, the seven-day finding has a separate citation; this source supports the longer-treatment finding. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Evidence from studies showing effects on emotional processing following nonpharmacological treatments for depression such as vagus nerve stimulation78 and negative ion treatment79 provide some preliminary evidence for the utility of the model in testing treatments with diverse mechanisms of action.”
§ The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment > Can human models of emotional processing be used to discriminate between effective and noneffective putative antidepressant treatments?
What the sources say
- Supportedcites [78] Critchley HD. Lewis PA. Orth M. et al Vagus nerve stimulation for treatment-resistant depression: behavioral and neural effects on encoding negative material. Psychosom Med. 2007 69 2 17 22 17244844 PMC2080822 source
The Discussion describes a single-patient proof of principle: active vagus nerve stimulation selectively disrupted encoding of negative material. This supports the cited VNS example of an effect on emotional processing. The paper does not address negative ion treatment, which the citing sentence attributes to a different reference. (LLM, conf=0.92)
- Supportedcites [79] Malcolm CP. Cowen PJ. Harmer CJ. High-density negative ion treatment increases positive affective memory. Psychol Med. 2009 39 11 1930 1932 19619385 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent work suggests that it is possible to measure affective biases in rodents using simple learning and subsequent preference tasks.86”
§ The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment > Why do some antidepressant drugs work so quickly?
What the sources say
- Supportedcites [86] Stuart SA. Butler P. Munafo MR. Nutt DJ. Robinson E. Distinct neuropsychological mechanisms may explain delayed- versus rapid-onset antidepressant efficacy. Neuropsychopharmacology. 2015 40 9 2165 2174 25740288 PMC4487826 source
The Introduction describes a rodent affective-bias test in which rats learn two food-reward associations and their subsequent choices are recorded in a preference test. The Materials and Methods section details the learning sessions and preference test. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It has been suggested that the modification of emotional bias may be the final common pathway by which all antidepressant drug treatments exert their positive effects on mood,10-12 and we have reviewed evidence from drugs with diverse pharmacological actions to support this.”
§ The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment > Why do some antidepressant drugs work so quickly?
What the sources say
- Partly supportedcites [10] Harmer C. Goodwin G. Cowen P. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009 195 2 102 108 19648538 sourceExperimental — accuracy not yet measured
The Conclusions (and Fig. 1 legend) of our copy do advance the hypothesis the citing sentence attributes: antidepressants 'do not act as direct mood enhancers but rather change the relative balance of positive to negative emotional processing', with early changes in emotional processing 'proposed to precede and ultimately contribute to later changes in mood', and the delay 'largely mediated by the translation of changes in emotional bias to mood'. However, the universal/'final common pathway' element is not supported: Future challenges states 'It is unclear, at present, whether all effective treatments for depression will have similar effects on emotional processing' and calls for further work on whether such changes are necessary or sufficient, while the Conclusions add that bias change 'may provide a platform for subsequent cognitive and psychological reconsolidation' together with slowly emerging downstream neuroadaptive effects — i.e. one contributing mechanism, not the sole final pathway for all antidepressants. (LLM, conf=0.75)
- Supportedcites [11] Roiser J. Elliott R. Sahakian B. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology. 2012 37 1 117 136 21976044 PMC3238070 source
The section 'Antidepressant Medication Effects on Affective Processing in Depressed Patients' states that 'according to the cognitive neuropsychological model of depression, the main beneficial effect of antidepressant drug action is to eliminate or reverse negative affective biases in depressed patients,' and 'The Cognitive Neuropsychological Model of Depression' states that pharmacological interventions 'do not affect mood directly' but instead 'alter the brain's processing of affective stimuli, allowing the learned states of dysphoria and anhedonia to remit gradually as the bottom-up biases contributing to them are attenuated or abolished' — i.e., bias modification as the common route of drug action. 'Predicting Differential Response to Treatment' likewise refers to 'the central tenet of the cognitive neuropsychological model that monoamine medications exert their effects by attenuating or reversing low-level negative affective biases.' The paper's hedged framing ('proposed', 'model') matches the claim's 'it has been suggested ... may be', and the review does survey drugs of differing action (SSRIs, NRI/SNRIs such as citalopram, reboxetine, venlafaxine), so the paraphrase is carried by our copy; only the exact phrase 'final common pathway' is the citing authors' wording. (LLM, conf=0.85)
- Partly supportedcites [12] Elliott R. Zahn R. Deakin W. Anderson I. Affective cognition and its disruption in mood disorders. Neuropsychopharmacology. 2011 36 1 153 182 20571485 PMC3055516 sourceExperimental — accuracy not yet measured
Our copy of Elliott et al. (2011) does discuss antidepressants and emotional bias: §5.4 (Summary) says negative biases 'may represent an important target for treatment (Clark et al., 2009; Harmer et al., 2010)', the annotated reference list (ref. 167) notes that 'negative biases respond acutely to antidepressants, prior to mood effects', and §9.4 states that 'Harmer et al. (2010) have argued that emotional memory ... may represent a biomarker for effective antidepressant drug action'. That covers the general idea that bias modification is involved in antidepressant action, but the paper nowhere asserts the stronger claim that it is the 'final common pathway' by which ALL antidepressants exert their mood effects — the comparable argument is hedged ('may') and credited to Harmer et al. (2010)/Clark et al. (2009). Indeed §§7.4.2–7.4.4 and 7.5.3 review largely null or confounded findings ('the role of 5-HT in these improvements is not clear'), so the universal mechanistic claim attributed here goes beyond, and is not supported by, this source. (LLM, conf=0.75)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Using this approach, it was possible to differentiate between the effects of the serotonin and noradrenaline reuptake inhibitor venlafaxine (delayed onset) and the NMDA receptor antagonist ketamine (rapid onset).”
§ The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment > Why do some antidepressant drugs work so quickly?
What the sources say
- Supportedcites [86] Stuart SA. Butler P. Munafo MR. Nutt DJ. Robinson E. Distinct neuropsychological mechanisms may explain delayed- versus rapid-onset antidepressant efficacy. Neuropsychopharmacology. 2015 40 9 2165 2174 25740288 PMC4487826 source
The Introduction describes using the rodent affective bias test to compare delayed-onset venlafaxine with rapid-onset ketamine. It reports different effects: only ketamine attenuated previously induced negative biases, while venlafaxine induced a positive bias during new learning and ketamine did not. (LLM, conf=0.93)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
50 more claims
Create a free account to see all 75 claims and to verify the 67 references still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in line with 5-HT dysfunction suggested to primarily result in the production of negative affect, i.e. sadness, and that of NA and DA, in a loss of positive affect and anhedonia (Pringle and Harmer 2015, Selvaraj et al. 2015).”
From Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment (2021) · cites this paper as Pringle and Harmer 2015
In the citing paper
“SSRIs seem to act primarily on the ‘negative’ aspects of emotional processing (e.g. decrease fear recognition and normalize exaggerated amygdala response to fearful faces), while NRIs are thought to primarily increase its ‘positive’ aspects (e.g. increase response to rewarding cues).”
From Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment (2021) · cites this paper as Pringle and Harmer 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment > References
“Br J Psychiatry. 2015 206 5 385”
§ The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment > References
“385 382 25745133”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment > References
“Psychol Med. 2012 41 12 2609”
§ The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment > References
“2609 2017 22716999”
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Bower, G. H. (1981) · American Psychologist · doi:10.1037/0003-066x.36.2.129 · Cited by 4,154
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492
Cognition and Depression: Current Status and Future Directions
Gotlib, I. H., & Joormann, J. (2010) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.121208.131305 · Cited by 2,420
Is there a universal need for positive self-regard?
Heine, S. J., Lehman, D. R., Markus, H. R., & Kitayama, S. (1999) · Psychological Review · doi:10.1037/0033-295x.106.4.766 · Cited by 2,247
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
Cognitive vulnerability to emotional disorders
Mathews, A., & MacLeod, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143916 · Cited by 2,100
Neural mechanisms of the cognitive model of depression.
Disner, S. G., Beevers, C. G., Haigh, E. A. P., & Beck, A. T. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3027 · Cited by 1,718
MacLeod, C., Rutherford, E., Campbell, L., Ebsworthy, G., & Holker, L. (2002) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.111.1.107 · Cited by 1,334
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230
Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors
Kramer, M. S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J. J., Reines, S. A., Liu, G., Snavely, D., Wyatt-Knowles, E., et al. (1998) · Science · doi:10.1126/science.281.5383.1640 · Cited by 1,071
Role of 5-HT in stress, anxiety, and depression
Graeff, F. G., Guimarães, F. S., De Andrade, T. G. C. S., & Deakin, J. F. W. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02135-3 · Cited by 984
Social cognition and the human brain
Adolphs, R. (1999) · Trends in Cognitive Sciences · doi:10.1016/s1364-6613(99)01399-6 · Cited by 895
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Fu, C. H. Y., Williams, S. C. R., Cleare, A. J., Brammer, M. J., Walsh, N. D., Kim, J., Andrew, C. M., Pich, E. M., Williams, P. M., Reed, L. J., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.9.877 · Cited by 775
Harmer, C. J., Shelley, N. C., Cowen, P. J., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1256 · Cited by 554
Self-citationHarmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051193 · Cited by 542
Self-citationCognitive Mechanisms of Treatment in Depression
Roiser, J. P., Elliott, R., & Sahakian, B. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.183 · Cited by 535
GLOWINSKI, J., & AXELROD, J. (1964) · Nature · doi:10.1038/2041318a0 · Cited by 512
Effect of Acute Antidepressant Administration on Negative Affective Bias in Depressed Patients
Harmer, C. J., O’Sullivan, U., Favaron, E., Massey-Chase, R., Ayres, R., Reinecke, A., Goodwin, G. M., & Cowen, P. J. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020149 · Cited by 485
Self-citationAntidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues
Harmer, C. J., Mackay, C. E., Reid, C. B., Cowen, P. J., & Goodwin, G. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.015 · Cited by 450
Self-citationAcute SSRI Administration Affects the Processing of Social Cues in Healthy Volunteers
Harmer, C. J., Bhagwagar, Z., Perrett, D. I., Völlm, B. A., Cowen, P. J., & Goodwin, G. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300004 · Cited by 420
Self-citationVictor, T. A., Furey, M. L., Fromm, S. J., Öhman, A., & Drevets, W. C. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.144 · Cited by 400
Coherence and Specificity of Information-Processing Biases in Depression and Social Phobia.
Gotlib, I. H., Kasch, K. L., Traill, S., Joormann, J., Arnow, B. A., & Johnson, S. L. (2004) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.113.3.386 · Cited by 396
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
Meta-analysis of emotion recognition deficits in major depressive disorder
Dalili, M. N., Penton-Voak, I. S., Harmer, C. J., & Munafò, M. R. (2015) · Psychological Medicine · doi:10.1017/s0033291714002591 · Cited by 349
Self-citationAffective Cognition and its Disruption in Mood Disorders
Elliott, R., Zahn, R., Deakin, J. F. W., & Anderson, I. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.77 · Cited by 330
The role of substance P in stress and anxiety responses
Ebner, K., & Singewald, N. (2006) · Amino Acids · doi:10.1007/s00726-006-0335-9 · Cited by 306
Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286
Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis
Ma, Y. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.24 · Cited by 270
Negative self‐schemata in clinical depression
Bradley, B., & Mathews, A. (1983) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1983.tb00598.x · Cited by 264
Harmer, C. J., Hill, S. A., Taylor, M. J., Cowen, P. J., & Goodwin, G. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.5.990 · Cited by 262
Self-citationKramer, M. S., Winokur, A., Kelsey, J., Preskorn, S. H., Rothschild, A. J., Snavely, D., Ghosh, K., Ball, W. A., Reines, S. A., Munjack, D., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300260 · Cited by 256
Effect of a single dose of citalopram on amygdala response to emotional faces
Murphy, S. E., Norbury, R., O'Sullivan, U., Cowen, P. J., & Harmer, C. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.056093 · Cited by 255
Self-citationBrowning, M., Holmes, E. A., & Harmer, C. J. (2010) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/cabn.10.1.8 · Cited by 247
Self-citationA single dose of citalopram increases fear recognition in healthy subjects
Browning, M., Reid, C., Cowen, P. J., Goodwin, G. M., & Harmer, C. J. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106074062 · Cited by 245
Self-citationShort-term SSRI treatment normalises amygdala hyperactivity in depressed patients.
Godlewska, B. R., Norbury, R., Selvaraj, S., Cowen, P. J., & Harmer, C. J. (2012) · Psychological Medicine · doi:10.1017/s0033291712000591 · Cited by 244
Self-citationNeuronal plasticity and antidepressant actions
Castrén, E., & Hen, R. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.12.010 · Cited by 243
Drevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241
(1992) · PubMed · Cited by 226
Escitalopram effects on insula and amygdala BOLD activation during emotional processing
Arce, E., Simmons, A. N., Lovero, K. L., Stein, M. B., & Paulus, M. P. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1004-8 · Cited by 198
Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
Kent, J. M., Coplan, J. D., & Gorman, J. M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00210-8 · Cited by 196
Williams, L. M., Korgaonkar, M. S., Song, Y. C., Paton, R., Eagles, S., Goldstein-Piekarski, A., Grieve, S. M., Harris, A. W. F., Usherwood, T., & Etkin, A. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.89 · Cited by 195
Gotlib, I. H., & Asarnow, R. F. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.1.86 · Cited by 187
Tranter, R., Bell, D., Gutting, P., Harmer, C., Healy, D., & Anderson, I. M. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.028 · Cited by 184
Self-citationKetamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172
Acute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity
Bigos, K. L., Pollock, B. G., Aizenstein, H. J., Fisher, P. M., Bies, R. R., & Hariri, A. R. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.52 · Cited by 164
Grillon, C., Levenson, J., & Pine, D. S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301204 · Cited by 162
Hayward, G., Goodwin, G. M., Cowen, P. J., & Harmer, C. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.016 · Cited by 162
Self-citationDelayed pharmacological effects of antidepressants
Frazer, A., & Benmansour, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001015 · Cited by 160
5-HT and depression: is the glass half-full?
Sharp, T., & Cowen, P. J. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.003 · Cited by 153
Are We Getting Closer to Valid Translational Models for Major Depression?
Berton, O., Hahn, C.-G., & Thase, M. E. (2012) · Science · doi:10.1126/science.1222940 · Cited by 148
Efficacy markers in depression
Harmer, C. J., Cowen, P. J., & Goodwin, G. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110367722 · Cited by 122
Self-citationWindischberger, C., Lanzenberger, R., Holik, A., Spindelegger, C., Stein, P., Moser, U., Gerstl, F., Fink, M., Moser, E., & Kasper, S. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.013 · Cited by 114
Norbury, R., Mackay, C. E., Cowen, P. J., Goodwin, G. M., & Harmer, C. J. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.031393 · Cited by 111
Self-citationShiroma, P. R., Thuras, P., Johns, B., & Lim, K. O. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4104 · Cited by 110
Short-term antidepressant treatment modulates amygdala response to happy faces
Norbury, R., Taylor, M. J., Selvaraj, S., Murphy, S. E., Harmer, C. J., & Cowen, P. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1597-1 · Cited by 109
Self-citationDirect effects of diazepam on emotional processing in healthy volunteers
Murphy, S. E., Downham, C., Cowen, P. J., & Harmer, C. J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1082-2 · Cited by 98
Self-citationTHE EFFECT OF IPRONIAZID AND IMIPRAMINE ON THE BLOOD PLATELET 5‐HYDROXYTRYPTAMINE LEVEL IN MAN
MARSHALL, E. F., STIRLING, G. S., TAIT, A. C., & TODRICK, A. (1960) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1960.tb01207.x · Cited by 96
Murphy, S. E., Yiend, J., Lester, K. J., Cowen, P. J., & Harmer, C. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009164 · Cited by 90
Self-citationConverging evidence for central 5-HT effects in acute tryptophan depletion
Crockett, M. J., Clark, L., Roiser, J. P., Robinson, O. J., Cools, R., Chase, H. W., den Ouden, H. E. M., Apergis-Schoute, A. M., Campbell-Meiklejohn, D. K., Seymour, B., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.106 · Cited by 81
Agomelatine facilitates positive versus negative affective processing in healthy volunteer models
Harmer, C. J., de Bodinat, C., Dawson, G. R., Dourish, C. T., Waldenmaier, L., Adams, S., Cowen, P. J., & Goodwin, G. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110376689 · Cited by 77
Self-citationEarly effects of mirtazapine on emotional processing
Arnone, D., Horder, J., Cowen, P. J., & Harmer, C. J. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1410-6 · Cited by 74
Self-citationStuart, S. A., Butler, P., Munafò, M. R., Nutt, D. J., & Robinson, E. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.59 · Cited by 71
Horder, J., Cowen, P. J., Di Simplicio, M., Browning, M., & Harmer, C. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1517-4 · Cited by 69
Self-citationHarmer, C. J., Heinzen, J., O’Sullivan, U., Ayres, R. A., & Cowen, P. J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1058-7 · Cited by 69
Self-citationA single dose of mirtazapine modulates neural responses to emotional faces in healthy people
Rawlings, N. B., Norbury, R., Cowen, P. J., & Harmer, C. J. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1983-8 · Cited by 65
Self-citationCritchley, H. D., Lewis, P. A., Orth, M., Josephs, O., Deichmann, R., Trimble, M. R., & Dolan, R. J. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31802e106d · Cited by 49
Horder, J., Browning, M., Di Simplicio, M., Cowen, P. J., & Harmer, C. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111400649 · Cited by 48
Self-citationBrowning, M., Grol, M., Ly, V., Goodwin, G. M., Holmes, E. A., & Harmer, C. J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.159 · Cited by 42
Self-citationA single dose of antidepressant alters eye-gaze patterns across face stimuli in healthy women
Jonassen, R., Chelnokova, O., Harmer, C., Leknes, S., & Landrø, N. I. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3729-5 · Cited by 39
Self-citationEffects of diazepam on facial emotion recognition
Coupland, N. J., Singh, A. J., Sustrik, R. A., Ting, P. T., & Blair, J. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0353 · Cited by 38
Pringle, A., McCabe, C., Cowen, P., & Harmer, C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112474523 · Cited by 37
Self-citationNK 1 receptor antagonism and emotional processing in healthy volunteers
Chandra, P., Hafizi, S., Massey-Chase, R., Goodwin, G., Cowen, P., & Harmer, C. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109103101 · Cited by 30
Self-citationDi Simplicio, M., Doallo, S., Costoloni, G., Rohenkohl, G., Nobre, A. C., & Harmer, C. J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.159 · Cited by 26
Self-citationE. Murphy, S. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791293051 · Cited by 26
Harmer, C. J., Dawson, G. R., Dourish, C. T., Favaron, E., Parsons, E., Fiore, M., Zucchetto, M., Bifone, A., Poggesi, I., Fernandes, S., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112472558 · Cited by 24
Self-citationAllelic variation in 5-HTTLPR and the effects of citalopram on the emotional neural network
Ma, Y., Li, B., Wang, C., Zhang, W., Rao, Y., & Han, S. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.150128 · Cited by 23
Pringle, A., Parsons, E., Cowen, L., McTavish, S., Cowen, P., & Harmer, C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112446535 · Cited by 21
Self-citationRuhé, H. G., Koster, M., Booij, J., van Herk, M., Veltman, D. J., & Schene, A. H. (2014) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2013.12.003 · Cited by 20
Short-term NK1 receptor antagonism and emotional processing in healthy volunteers
Pringle, A., McTavish, S. F., Williams, C., Smith, R., Cowen, P. J., & Harmer, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2133-z · Cited by 18
Self-citationResearch Letter: High-density negative ion treatment increases positive affective memory
MALCOLM, C. P., COWEN, P. J., & HARMER, C. J. (2009) · Psychological Medicine · doi:10.1017/s0033291709990444 · Cited by 18
Self-citation
Research works printed but not linked: 5
- Beck AT. Rush AJ. Shaw BF. Emery G. Cognitive Therapy of Depression. New York, NY: Guilford; 1979
- Williams JMG. Watts FN. MacLeod C. Mathews A. Cognitive Psychology and Emotional Disorders. Oxford, UK: John Wiley and Sons; 1988
- Godlewska BR. Browning M. Norbury R. Cowen PJ. Harmer CJ. Early changes in neural response to emotional stimuli predict clincial reponse to ssri treatment in depression. J Psychopharmacol. 28(8 Abstract Supplement): Abstract 2014
- Brown GW. Harris T. Social Origins of Depression. London, U K: Tavistock Publications; 1978
- Deakin JW. Williams S. Downey D. et al PharmacoMRI and cognitive effects of the low-trapping NMDA channel blocker AZD6765 compared with ketamine in untreated major depressive disorder. Abstract presented at: 28th CINP World Congress of Neuropsychopharmacology. Stockholm, Sweden, Biol Psychiatry. 2012
Cited by
Irritability in Youths: A Translational Model
Brotman, M. A., Kircanski, K., Stringaris, A., Pine, D. S., & Leibenluft, E. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16070839 · Cited by 362
Godlewska, B. R., & Harmer, C. J. (2021) · Psychopharmacology · doi:10.1007/s00213-019-05448-0 · Cited by 123
Self-citationModeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences
Grillon, C., Robinson, O. J., Cornwell, B., & Ernst, M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0445-1 · Cited by 82
Rocha, J. M., Rossi, G. N., de Lima Osório, F., Bouso, J. C., de Oliveira Silveira, G., Yonamine, M., Campos, A. C., Bertozi, G., Cecílio Hallak, J. E., & dos Santos, R. G. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001396 · Cited by 46
Hinchcliffe, J. K., Stuart, S. A., Mendl, M., & Robinson, E. S. J. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4687-5 · Cited by 45
Metadata
- Authors
- Pringle, A., & Harmer, C. J.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Harmer, Catherine J.
- ORCID
- Harmer, Catherine J.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2015-12-31
- Volume
- 17
- Issue
- 4
- Pages
- 477-487
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- PMC
- PMC4734885
- OpenAlex
- W2259267629
- Cited by
- 61
- References
- 83
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 26 · 2020: 4 · 2019: 8 · 2018: 6 · 2017: 2 · 2016: 2
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- antidepressants, emotional processing, emotional bias, depression, healthy volunteers, treatment response prediction, personalized treatment
- MeSH terms
- Affect, Animals, Antidepressive Agents, Depression, Depressive Disorder, Emotions, Humans, Memory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.